Altretamine
Top View
- NTP Monograph on the Systematic Review of Occupational Exposure to Cancer Chemotherapy Agents and Adverse Health Outcomes
- Perioperative Medication Management - Adult/Pediatric - Inpatient/Ambulatory Clinical Practice Guideline
- In Vitro Chemosensitivity Using the Histoculture Drug Response Assay in Human Epithelial Ovarian Cancer
- Methotrexate 25Mg/Ml Solution for Injection - Summary of Product Characteristics (SPC) - (Emc)
- Altretamine (Hexalen®) (“Al TRET a Meen”)
- Carboplatin, Doxorubicin and Etoposide in the Treatment of Tumours of Unknown Primary Site
- Medications That Are Immunosuppressive Or Immunomodulatory (This List Is Not All-Inclusive)
- Emetogenic Potential of Antineoplastic Agents
- The Cost Burden of Blood Cancer Care in Medicare a Longitudinal Analysis of Medicare Advantage and Fee for Service Patients Diagnosed with Blood Cancer
- Chemotherapy-Induced Peripheral Neuropathy: a Literature Review Neuropatia Periférica Induzida Por Quimioterapia: Uma Revisão De Literatura
- From Old Alkylating Agents to New Minor Groove Binders
- Pharmacist Involvement in the Management of Adverse Effects
- Hemodialysis Drug Removal
- Supplementary Table 1. Summary of FDA-Approved Anticancer Cytotoxic Drugs at May 2019
- Guide for Handling Cytotoxic Drugs and Related Waste
- Oncology Agents Not Listed in Seer Book 8
- List of Off-Patent, Off-Exclusivity Drugs Without an Approved Generic
- Emetogenic Potential of Antineoplastic Agents